{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:57:38Z","timestamp":1762419458037,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.rgmxen.2021.09.005","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T07:36:10Z","timestamp":1651563370000},"page":"455-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals"],"prefix":"10.1016","volume":"87","author":[{"given":"I.","family":"Santana-Salgado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bautista-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Moreno-Alc\u00e1ntar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmxen.2021.09.005_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0015","unstructured":"National cancer institute: Surveillance, epidemiology and end results program. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html. [Accessed 1 August 2020]."},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0030","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0045","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3748\/wjg.v24.i24.2582","article-title":"Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows","volume":"24","author":"Guarino","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0055","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0065","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2016.07.004","article-title":"Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution","volume":"65","author":"Nault","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0075","first-page":"33","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen","volume":"68","author":"Innes","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0080","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0085","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules","volume":"70","author":"Mari\u00f1o","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virusres.2010.03.009","article-title":"Molecular epidemiology of hepatitis C virus genotypes in west Mexico","volume":"151","author":"Panduro","year":"2010","journal-title":"Virus Res"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.14380","article-title":"Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment","volume":"47","author":"Ogawa","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmxen.2021.09.005_bib0100","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and metaregression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255534X22000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255534X22000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:53:38Z","timestamp":1762419218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2255534X22000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2255534X22000251"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmxen.2021.09.005","relation":{},"ISSN":["2255-534X"],"issn-type":[{"type":"print","value":"2255-534X"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmxen.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmx.2021.09.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}